Table 1 Distribution of vascular occlusion cases
From: Retinal vascular occlusion in patients with the Covid-19 virus
n | Diagnosis | Gender | Age | Days until symptoms | VA i | VA f | Severity of COVID | Commorbility | Hospitalization | Treatment |
|---|---|---|---|---|---|---|---|---|---|---|
1 | CRVO | M | 52 | 22 | 20/400 | 20/20 | + | No | No | Anti VEGF |
2 | M | 65 | 90 | 20/1000 | 20/400 | + + | No | No | Anti VEGF | |
3 | F | 37 | 45 | 20/20 | 20/20 | + + | No | No | No | |
4 | M | 46 | 50 | 20/40 | 20/20 | + + | No | No | Anti VEGF | |
5 | F | 27 | 7 | 20/60 | 20/20 | + + | No | No | Anti VEGF | |
6 | M | 36 | 55 | 20/20 | 20/20 | + | No | No | No | |
7 | M | 41 | 45 | 20/40 | 20/30 | + + + | Dyslip | No | Anti VEGF | |
8 | M | 41 | 55 | 20/400 | 20/50 | + + | No | No | Anti VEGF | |
9 | HMVO | M | 43 | 7 | 20/50 | 20/30 | + + + | No | Yes | Anti VEGF |
10 | BRVO | F | 54 | 7 | 20/25 | 20/20 | + | No | No | Ketorolac d |
11 | M | 36 | 90 | 20/30 | 20/20 | + | No | No | Anti VEGF | |
12 | M | 64 | 7 | CF | 20/200 | + + | No | No | Anti VEGF | |
13 | CRAO | M | 73 | 7 | LP | LP | + + + + | DM + HBP | Yes | No |
14 | M | 47 | 7 | LP | LP | + + + + | No | Yes | No |